Daniel Joseph McCarthy - 01 Jul 2025 Form 4 Insider Report for Evolent Health, Inc. (EVH)

Reporting relationship: PRESIDENT
Issuer ticker: EVH
Reported as of: 01 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jul 2025, 07:08:19 UTC
Prior SEC filing: 10 Mar 2025
Next SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Weinberg, Attorney-in-fact

Key filing fact

Daniel Joseph McCarthy filed Form 4 for Evolent Health, Inc. (EVH) on 03 Jul 2025.

Key facts

This page summarizes Daniel Joseph McCarthy's Form 4 filing for Evolent Health, Inc. (EVH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jul 2025, 07:08.

Change

Previous filing in this sequence was filed on 10 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001946147 Primary reporting owner

McCarthy Daniel Joseph

Relationship: PRESIDENT
Address: C/O EVOLENT HEALTH, INC., 1812 N. MOORE ST., STE. 1705, ARLINGTON
Signature: /s/ Jonathan Weinberg, Attorney-in-fact
Signature date: 03 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVH transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +44,767
Change %: +12%
Price: $0.000000
Shares after: 433,771
Date: 01 Jul 2025
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents restricted stock units granted to Mr. McCarthy pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

Footnote F2

Securities vest at a rate of 34% on July 1, 2026, and 33% on July 1, 2027, and July 1, 2028.

Footnote F3

Represents a portion of the award approved by the Compensation Committee of the Company's Board of Directors as part of the annual award cycle. The first portion of the award was granted on March 3, 2025, and this portion of the award was contingent upon the approval of the issuance of additional shares under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. The Company's shareholders approved the issuance of additional shares under the Amended and Restated 2015 Omnibus Incentive Compensation Plan on June 5, 2025, at the Company's Annual Meeting.

Footnote F4

Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.